Key Points Moderna's recent success in a phase 3 clinical trial for its personalized cancer vaccine was a breakthrough. This product could rival the lifetime sales of Moderna's coronavirus vaccine. Moderna's deep pipeline makes the stock even more attractive. 10 stocks we like better than Moderna › Moderna (NASDAQ: MRNA) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies. This new product should meaningfully contribute to the biotech's financial results over the medium term.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.